Educational Book - ASCO Annual Meeting - American Society of ...

English
chicago2013.asco.org - 4 other Mags
Educational Book - ASCO Annual Meeting - American Society of ...
|
905 Pages
|
126
|
0 Views
|
Educational Book - ASCO Annual Meeting - American Society of ... Inappropriate

Educational Book - ASCO Annual Meeting - American Society of

AMERICAN SOCIETY OF CLINICAL ONCOLOGY 2013 EDUCATIONAL BOOK “Building Bridges to Conquer Cancer” 49th Annual Meeting | May 31-June 4, 2013 | Chicago, Illinois | Volume 33

  • Page 2: American Society of Clinical Oncolo
  • Page 5: Contents
  • Page 7: Soy Isoflavones and Breast Cancer
  • Page 9: Raising the Bar: Can We Diminish th
  • Page 11: Pathways in Gynecologic Malignancie
  • Page 13: Current Clinical Controversies in M
  • Page 15: Stories We Tell One Another: Narrat
  • Page 17: TUMOR BIOLOGY
  • Page 19: 2012-2013 Cancer Education Committe
  • Page 21: John Frederick De Groot, MD
  • Page 23: Robert J. Mayer, MD
  • Page 25: Timothy Joseph Whelan, BM, BCh, MSc
  • Page 27: Lee Helman, MD
  • Page 29: 2013 Annual Meeting Supporters*
  • Page 31: Letter from the Editor
  • Page 33: Adjuvant Chemotherapy: Which Patien
  • Page 35: tion, or lymphovascular invasion wo
  • Page 37: should ideally be directed at bette
  • Page 39: Early and Late Long-Term Effects of
  • Page 41: CARDIAC DYSFUNCTION
  • Page 43: References
  • Page 45: Translating Genomic Research into C
  • Page 47: TABLE 1. Glossary of Terms Commonly
  • Page 49: TABLE 2. Summary of Selected Next-G
  • Page 51: hypomethylated phenotype that overl
  • Page 53:

    17. Stephens PJ, McBride DJ, Lin ML

  • Page 55:

    ZARDAVAS ET AL

  • Page 57:

    ZARDAVAS ET AL

  • Page 59:

    ZARDAVAS ET AL

  • Page 61:

    ZARDAVAS ET AL

  • Page 63:

    ZARDAVAS ET AL

  • Page 65:

    BREAST CANCER

  • Page 67:

    PEREZ-GARCIA, MUÑOZ-COUSELO, AND C

  • Page 69:

    PEREZ-GARCIA, MUÑOZ-COUSELO, AND C

  • Page 71:

    PEREZ-GARCIA, MUÑOZ-COUSELO, AND C

  • Page 73:

    STRASSER-WEIPPL AND GOSS

  • Page 75:

    STRASSER-WEIPPL AND GOSS

  • Page 77:

    STRASSER-WEIPPL AND GOSS

  • Page 79:

    STRASSER-WEIPPL AND GOSS

  • Page 81:

    JULIA WHITE

  • Page 83:

    JULIA WHITE

  • Page 85:

    JULIA WHITE

  • Page 87:

    IYENGAR, HUDIS, AND DANNENBERG

  • Page 89:

    IYENGAR, HUDIS, AND DANNENBERG

  • Page 91:

    IYENGAR, HUDIS, AND DANNENBERG

  • Page 93:

    LIGIBEL AND STRICKLER

  • Page 95:

    LIGIBEL AND STRICKLER

  • Page 97:

    LIGIBEL AND STRICKLER

  • Page 99:

    LIGIBEL AND STRICKLER

  • Page 101:

    BREAST CANCER

  • Page 103:

    HO AND CODY

  • Page 105:

    HO AND CODY

  • Page 107:

    GROBMYER, COWHER, AND CROWE

  • Page 109:

    GROBMYER, COWHER, AND CROWE

  • Page 111:

    GROBMYER, COWHER, AND CROWE

  • Page 113:

    BREAST CANCER

  • Page 115:

    RASTOGI ET AL

  • Page 117:

    RASTOGI ET AL

  • Page 119:

    RASTOGI ET AL

  • Page 121:

    BREAST CANCER

  • Page 123:

    JOCHELSON, HAYES, AND GANZ

  • Page 125:

    JOCHELSON, HAYES, AND GANZ

  • Page 127:

    JOCHELSON, HAYES, AND GANZ

  • Page 129:

    WILSON AND CHIA

  • Page 131:

    WILSON AND CHIA

  • Page 133:

    WILSON AND CHIA

  • Page 135:

    WILSON AND CHIA

  • Page 137:

    JOHNSTON AND SCHIAVON

  • Page 139:

    JOHNSTON AND SCHIAVON

  • Page 141:

    JOHNSTON AND SCHIAVON

  • Page 143:

    JOHNSTON AND SCHIAVON

  • Page 145:

    JOHNSTON AND SCHIAVON

  • Page 147:

    TODD W. MILLER

  • Page 149:

    TODD W. MILLER

  • Page 151:

    TODD W. MILLER

  • Page 153:

    RAYMOND AND STOFFEL

  • Page 155:

    RAYMOND AND STOFFEL

  • Page 157:

    RAYMOND AND STOFFEL

  • Page 159:

    Connecting Molecular Pathways to He

  • Page 161:

    BAP1 Function

  • Page 163:

    LFS develop gliomas, typically befo

  • Page 165:

    TABLE 2. Germline SDHx Mutations an

  • Page 167:

    13. Höiom V, Edsgärd D, Helgadott

  • Page 169:

    CANCER PREVENTION/EPIDEMIOLOGY

  • Page 171:

    a nonsignifıcant increased risk of

  • Page 173:

    OTHER INDICATIONS/USES OF GTPs

  • Page 175:

    Marine-Derived Omega-3 Fatty Acids:

  • Page 177:

    compliance with dosing and little i

  • Page 179:

    22. Yee LD, Young DC, Rosol TJ, et

  • Page 181:

    (95% CI, 0.65-0.86) in Asian popula

  • Page 183:

    menopausal status will be needed as

  • Page 185:

    CANCER PREVENTION/EPIDEMIOLOGY

  • Page 187:

    as BRCA germ-line mutations are exa

  • Page 189:

    FIG 1. IMPACT study design: Targete

  • Page 191:

    with predisposition to prostate can

  • Page 193:

    Mammographic Density and Risk of Br

  • Page 195:

    TABLE 1. Selected Characteristics o

  • Page 197:

    Prentice 25 [62] and further by Sch

  • Page 199:

    Mammographic Density: Intersection

  • Page 201:

    limits our ability to evaluate the

  • Page 203:

    FIG 3. Proposed algorithm for women

  • Page 205:

    east cancer risk and risk predictio

  • Page 207:

    MYRNA R. ROSENFELD

  • Page 209:

    MYRNA R. ROSENFELD

  • Page 211:

    MYRNA R. ROSENFELD

  • Page 213:

    M. J. VAN DEN BENT

  • Page 215:

    M. J. VAN DEN BENT

  • Page 217:

    Antiangiogenic Therapy for Glioblas

  • Page 219:

    eduction in cerebral edema and spar

  • Page 221:

    overcome this invasive phenotype in

  • Page 223:

    more reliably assess underlying tum

  • Page 225:

    CLINICAL TRIALS

  • Page 227:

    selection of treatment in subgroups

  • Page 229:

    BACKGROUND

  • Page 231:

    centers, industry, and regulatory a

  • Page 233:

    References

  • Page 235:

    PAUL B. CHAPMAN

  • Page 237:

    PAUL B. CHAPMAN

  • Page 239:

    MCCASKILL-STEVENS ET AL

  • Page 241:

    MCCASKILL-STEVENS ET AL

  • Page 243:

    MCCASKILL-STEVENS ET AL

  • Page 245:

    DEVELOPMENTAL THERAPEUTICS

  • Page 247:

    ANSELL AND VONDERHEIDE

  • Page 249:

    ANSELL AND VONDERHEIDE

  • Page 251:

    ANSELL AND VONDERHEIDE

  • Page 253:

    DEVELOPMENTAL THERAPEUTICS

  • Page 255:

    HOWARD A. BURRIS III

  • Page 257:

    HOWARD A. BURRIS III

  • Page 259:

    MATHUR AND WEINER

  • Page 261:

    MATHUR AND WEINER

  • Page 263:

    LESLIE AND YOUNES

  • Page 265:

    LESLIE AND YOUNES

  • Page 267:

    LESLIE AND YOUNES

  • Page 269:

    DEVELOPMENTAL THERAPEUTICS

  • Page 271:

    MUNOZ, SWANTON, AND KURZROCK

  • Page 273:

    MUNOZ, SWANTON, AND KURZROCK

  • Page 275:

    MUNOZ, SWANTON, AND KURZROCK

  • Page 277:

    MUNOZ, SWANTON, AND KURZROCK

  • Page 279:

    ABERNETHY ET AL

  • Page 281:

    ABERNETHY ET AL

  • Page 283:

    ABERNETHY ET AL

  • Page 285:

    ABERNETHY ET AL

  • Page 287:

    DAVIS, BRUERA, AND MORGANSTERN

  • Page 289:

    DAVIS, BRUERA, AND MORGANSTERN

  • Page 291:

    DAVIS, BRUERA, AND MORGANSTERN

  • Page 293:

    DAVIS, BRUERA, AND MORGANSTERN

  • Page 295:

    ANTONELLA SURBONE

  • Page 297:

    ANTONELLA SURBONE

  • Page 299:

    ANTONELLA SURBONE

  • Page 301:

    MATJAZ ZWITTER

  • Page 303:

    MATJAZ ZWITTER

  • Page 305:

    GASTROINTESTINAL (COLORECTAL) CANCE

  • Page 307:

    SCOTT KOPETZ

  • Page 309:

    SCOTT KOPETZ

  • Page 311:

    SCOTT KOPETZ

  • Page 313:

    VENOOK AND SALTZ

  • Page 315:

    VENOOK AND SALTZ

  • Page 317:

    HIRSCH AND SCHULMAN

  • Page 319:

    HIRSCH AND SCHULMAN

  • Page 321:

    HIRSCH AND SCHULMAN

  • Page 323:

    Approach to the Older Patient with

  • Page 325:

    DETERMINING APPROPRIATE THERAPY IN

  • Page 327:

    ecurrence. In those with a lower ri

  • Page 329:

    Achieving Health Equity in Colorect

  • Page 331:

    FIG 2. Colorectal cancer screening

  • Page 333:

    also need to put further emphasis o

  • Page 335:

    Cancer of Unknown Primary Site: Imp

  • Page 337:

    FIG 1. Evaluation and management of

  • Page 339:

    A molecular profıle assay appears

  • Page 341:

    References

  • Page 343:

    PRESENTATION, IMAGING, AND DIAGNOSI

  • Page 345:

    TABLE 1. Select Results of CRS plus

  • Page 347:

    may be reasonable to assume similar

  • Page 349:

    Rare but Real: Management of Small

  • Page 351:

    adjuvant therapy in higher-risk pat

  • Page 353:

    pathogenesis of neoplasia in the sm

  • Page 355:

    PHILIP J. JOHNSON

  • Page 357:

    PHILIP J. JOHNSON

  • Page 359:

    PHILIP J. JOHNSON

  • Page 361:

    KELLEY AND VENOOK

  • Page 363:

    KELLEY AND VENOOK

  • Page 365:

    KELLEY AND VENOOK

  • Page 367:

    DANIEL COIT

  • Page 369:

    DANIEL COIT

  • Page 371:

    DANIEL COIT

  • Page 373:

    DANIEL COIT

  • Page 375:

    HAUSTERMANS

  • Page 377:

    HAUSTERMANS

  • Page 379:

    MANISH A. SHAH

  • Page 381:

    MANISH A. SHAH

  • Page 383:

    GENITOURINARY CANCER

  • Page 385:

    KARIM FIZAZI

  • Page 387:

    KARIM FIZAZI

  • Page 389:

    GULLEY, MADAN, AND HEERY

  • Page 391:

    GULLEY, MADAN, AND HEERY

  • Page 393:

    GULLEY, MADAN, AND HEERY

  • Page 395:

    Targeting Molecular Aberrations in

  • Page 397:

    TABLE 2. Selected Clinical Trials o

  • Page 399:

    19. Aftab DT, McDonald DM. MET and

  • Page 401:

    FIG 1. The United States trimodalit

  • Page 403:

    FIG 3. Patterns of recurrence after

  • Page 405:

    adiotherapy or cystectomy in Yorksh

  • Page 407:

    GENITOURINARY CANCER

  • Page 409:

    therapies may play a role. 9 PFS ha

  • Page 411:

    GENITOURINARY CANCER

  • Page 413:

    a PSA level of 10 or higher, and su

  • Page 415:

    TABLE 2. Features of Hypogonadism v

  • Page 417:

    delaying development of castration

  • Page 419:

    androgen suppression on androgen-de

  • Page 421:

    KLEPIN ET AL

  • Page 423:

    KLEPIN ET AL

  • Page 425:

    KLEPIN ET AL

  • Page 427:

    KLEPIN ET AL

  • Page 429:

    KLEPIN ET AL

  • Page 431:

    KLEPIN ET AL

  • Page 433:

    GERIATRIC ONCOLOGY

  • Page 435:

    AJEET GAJRA

  • Page 437:

    AJEET GAJRA

  • Page 439:

    WU AND GOLDBERG

  • Page 441:

    WU AND GOLDBERG

  • Page 443:

    GYNECOLOGIC CANCER

  • Page 445:

    DAVID M. GERSHENSON

  • Page 447:

    DAVID M. GERSHENSON

  • Page 449:

    JAIN AND SEIDEN

  • Page 451:

    JAIN AND SEIDEN

  • Page 453:

    JAIN AND SEIDEN

  • Page 455:

    G. THOMAS

  • Page 457:

    G. THOMAS

  • Page 459:

    MATEI, BROWN, AND FRAZIER

  • Page 461:

    MATEI, BROWN, AND FRAZIER

  • Page 463:

    MATEI, BROWN, AND FRAZIER

  • Page 465:

    MATEI, BROWN, AND FRAZIER

  • Page 467:

    SALVESEN, WERNER, AND KRAKSTAD

  • Page 469:

    SALVESEN, WERNER, AND KRAKSTAD

  • Page 471:

    PENELOPE M. WEBB

  • Page 473:

    PENELOPE M. WEBB

  • Page 475:

    PENELOPE M. WEBB

  • Page 477:

    PENELOPE M. WEBB

  • Page 479:

    Pathologic Diagnosis, Origin, and N

  • Page 481:

    symptoms mimicking acute appendicit

  • Page 483:

    Classifıcation of Tumours of the D

  • Page 485:

    Treatment and Trials: Ovarian Cance

  • Page 487:

    e offered an alternative pathway, s

  • Page 489:

    aseline, and FIGO stage IV. The use

  • Page 491:

    severe toxicity from chemotherapy a

  • Page 493:

    48. Bukowski RM, Ozols RF, Markman

  • Page 495:

    Locally Advanced Head and Neck Canc

  • Page 497:

    followed by concurrent CRT to theor

  • Page 499:

    have also shown clinical benefıt i

  • Page 501:

    investigation is required to determ

  • Page 503:

    HEAD AND NECK CANCER

  • Page 505:

    adenosine-triphosphate competitive

  • Page 507:

    signaling in maintenance of the res

  • Page 509:

    Fig 2. Overview of Class 1 PI3K sig

  • Page 511:

    Based on preclinical data using an

  • Page 513:

    dependence through epithelial-to-me

  • Page 515:

    Salivary Gland Cancer: An Update on

  • Page 517:

    signaling pathway is a novel molecu

  • Page 519:

    Patients with ACC treated with radi

  • Page 521:

    inactivation of Apc and Pten in the

  • Page 523:

    SINGER, LANGENDIJK, AND YAROM

  • Page 525:

    SINGER, LANGENDIJK, AND YAROM

  • Page 527:

    SINGER, LANGENDIJK, AND YAROM

  • Page 529:

    STEPHEN T. SONIS

  • Page 531:

    STEPHEN T. SONIS

  • Page 533:

    STEPHEN T. SONIS

  • Page 535:

    DAVID KHAYAT

  • Page 537:

    DAVID KHAYAT

  • Page 539:

    CARLOS VALLEJOS

  • Page 541:

    CARLOS VALLEJOS

  • Page 543:

    Difficult to Swallow: Issues Affect

  • Page 545:

    setting, sometimes in the absence o

  • Page 547:

    Individual economic situations shou

  • Page 549:

    Disparities and Challenges in Adher

  • Page 551:

    greater than 80%. MPR is defıned a

  • Page 553:

    discontinue hormone therapy. Black

  • Page 555:

    HEALTH SERVICES RESEARCH

  • Page 557:

    prostate screening tests. Findings

  • Page 559:

    Although opponents to such plans fo

  • Page 561:

    HEALTH SERVICES RESEARCH

  • Page 563:

    three times higher likelihood of ac

  • Page 565:

    TABLE 1. Examples of Structure of S

  • Page 567:

    surgeon performance, and operating

  • Page 569:

    BEJAR ET AL

  • Page 571:

    BEJAR ET AL

  • Page 573:

    BEJAR ET AL

  • Page 575:

    BEJAR ET AL

  • Page 577:

    BEJAR ET AL

  • Page 579:

    BEJAR ET AL

  • Page 581:

    BEJAR ET AL

  • Page 583:

    BEJAR ET AL

  • Page 585:

    Biology and Treatment of Acute Lymp

  • Page 587:

    TABLE 2. Clinical Trials Evaluating

  • Page 589:

    16. Nachman JB, La MK, Hunger SP, e

  • Page 591:

    FIG 1. Practical approach for treat

  • Page 593:

    References

  • Page 595:

    47% and 57% in those who did not re

  • Page 597:

    schedule was selected as it appeare

  • Page 599:

    acute lymphocytic leukaemia: a phas

  • Page 601:

    The Role of JAK1/2 Inhibitors in th

  • Page 603:

    MF. The results of these trials hav

  • Page 605:

    Disclosures of Potential Conflicts

  • Page 607:

    FIG 1. Mechanisms of resistance in

  • Page 609:

    3-month transcript levels to be pre

  • Page 611:

    Disclosures of Potential Conflicts

  • Page 613:

    The Role of Kinase Inhibitors in th

  • Page 615:

    studies reported no responses in pa

  • Page 617:

    Disclosures of Potential Conflicts

  • Page 619:

    LUNG CANCER

  • Page 621:

    HETEROGENEITY OF PRESENTATIONS WITH

  • Page 623:

    The increased complexity of resista

  • Page 625:

    the recommendation for fırst-line

  • Page 627:

    LUNG CANCER

  • Page 629:

    TABLE 1. Trials of Preoperative Che

  • Page 631:

    the surgical resection. Third, preo

  • Page 633:

    29. Martins RG. Treatment of Locall

  • Page 635:

    LAURA QM CHOW

  • Page 637:

    LAURA QM CHOW

  • Page 639:

    LAURA QM CHOW

  • Page 641:

    LAURA QM CHOW

  • Page 643:

    MORSE ET AL

  • Page 645:

    MORSE ET AL

  • Page 647:

    MORSE ET AL

  • Page 649:

    LUNG CANCER

  • Page 651:

    CARLOS GIL FERREIRA

  • Page 653:

    CARLOS GIL FERREIRA

  • Page 655:

    NOWAK, CALVO, AND SORIA

  • Page 657:

    NOWAK, CALVO, AND SORIA

  • Page 659:

    NOWAK, CALVO, AND SORIA

  • Page 661:

    LUNG CANCER

  • Page 663:

    SHEPHERD, BUNN, AND PAZ-ARES

  • Page 665:

    SHEPHERD, BUNN, AND PAZ-ARES

  • Page 667:

    SHEPHERD, BUNN, AND PAZ-ARES

  • Page 669:

    SHEPHERD, BUNN, AND PAZ-ARES

  • Page 671:

    MORGENSZTERN, DEVARAKONDA, AND GOVI

  • Page 673:

    MORGENSZTERN, DEVARAKONDA, AND GOVI

  • Page 675:

    MORGENSZTERN, DEVARAKONDA, AND GOVI

  • Page 677:

    SCAGLIOTTI ET AL

  • Page 679:

    SCAGLIOTTI ET AL

  • Page 681:

    SCAGLIOTTI ET AL

  • Page 683:

    WARREN AND CUMMINGS

  • Page 685:

    WARREN AND CUMMINGS

  • Page 687:

    WARREN AND CUMMINGS

  • Page 689:

    Aberrant Epigenetic Regulation: A C

  • Page 691:

    FIG 1. Methylation and chromatin pa

  • Page 693:

    Epigenetic Therapy As a Primer for

  • Page 695:

    LYMPHOMA AND PLASMA CELL DISORDERS

  • Page 697:

    cell lines and has been shown to in

  • Page 699:

    TABLE 1. Selected List of Clinical

  • Page 701:

    Further work is needed now to not o

  • Page 703:

    LYMPHOMA AND PLASMA CELL DISORDERS

  • Page 705:

    Myeloma Working Group (IMWG) criter

  • Page 707:

    could continue with 6-week cycles b

  • Page 709:

    Update on the Initial Therapy of Mu

  • Page 711:

    TABLE 2. Summary of Post-ASCT Outco

  • Page 713:

    thalidomide HD dex. However, this

  • Page 715:

    New Tools for Diagnosis and Monitor

  • Page 717:

    MM and other plasma cell dyscrasias

  • Page 719:

    normal, focal, variegated, or diffu

  • Page 721:

    LYMPHOMA AND PLASMA CELL DISORDERS

  • Page 723:

    The transition from extended fıeld

  • Page 725:

    ABVD. Sixty-nine of 196 (35%) patie

  • Page 727:

    least modest exposure to the heart,

  • Page 729:

    MELANOMA/SKIN CANCERS

  • Page 731:

    However, despite these apparent adv

  • Page 733:

    include routine histopathology as o

  • Page 735:

    intraoperative lymphatic mapping an

  • Page 737:

    FRANCIS ET AL

  • Page 739:

    FRANCIS ET AL

  • Page 741:

    FRANCIS ET AL

  • Page 743:

    J. WILLIAM HARBOUR

  • Page 745:

    J. WILLIAM HARBOUR

  • Page 747:

    MELANOMA

  • Page 749:

    LONG AND MARGOLIN

  • Page 751:

    LONG AND MARGOLIN

  • Page 753:

    LONG AND MARGOLIN

  • Page 755:

    RAMAKRISHNA AND MARGOLIN

  • Page 757:

    RAMAKRISHNA AND MARGOLIN

  • Page 759:

    PATIENT AND SURVIVOR CARE

  • Page 761:

    TERESA GILEWSKI

  • Page 763:

    TERESA GILEWSKI

  • Page 765:

    DAVID P. STEENSMA

  • Page 767:

    DAVID P. STEENSMA

  • Page 769:

    PATIENT AND SURVIVOR CARE

  • Page 771:

    EL SAGHIR, ASSI, AND PYLE

  • Page 773:

    EL SAGHIR, ASSI, AND PYLE

  • Page 775:

    EL SAGHIR, ASSI, AND PYLE

  • Page 777:

    LICHTMAN

  • Page 779:

    PATIENT AND SURVIVOR CARE

  • Page 781:

    LYMAN, KHORANA, AND FALANGA

  • Page 783:

    LYMAN, KHORANA, AND FALANGA

  • Page 785:

    LYMAN, KHORANA, AND FALANGA

  • Page 787:

    LYMAN, KHORANA, AND FALANGA

  • Page 789:

    PEDIATRIC ONCOLOGY

  • Page 791:

    LABELLE AND CUNNINGHAM

  • Page 793:

    LABELLE AND CUNNINGHAM

  • Page 795:

    LABELLE AND CUNNINGHAM

  • Page 797:

    DAW AND MAHAJAN

  • Page 799:

    DAW AND MAHAJAN

  • Page 801:

    DAW AND MAHAJAN

  • Page 803:

    PEDIATRIC CANCER

  • Page 805:

    CAROLA A. S. ARNDT

  • Page 807:

    CAROLA A. S. ARNDT

  • Page 809:

    FERGUSON, HINGORANI, AND GUPTA

  • Page 811:

    FERGUSON, HINGORANI, AND GUPTA

  • Page 813:

    FERGUSON, HINGORANI, AND GUPTA

  • Page 815:

    ERIN R. RUDZINSKI

  • Page 817:

    ERIN R. RUDZINSKI

  • Page 819:

    SLEDGE, MILLER, AND HAUSER

  • Page 821:

    SLEDGE, MILLER, AND HAUSER

  • Page 823:

    SLEDGE, MILLER, AND HAUSER

  • Page 825:

    Understanding and Surviving the Tra

  • Page 827:

    care. Consultants in Medical Oncolo

  • Page 829:

    on chemotherapy costs, which accoun

  • Page 831:

    8. Applying the cancer cost savings

  • Page 833:

    PRACTICE MANAGEMENT AND

  • Page 835:

    the “home medications” section

  • Page 837:

    U.S. medical claims. Even before th

  • Page 839:

    PATEL AND TRAN

  • Page 841:

    PATEL AND TRAN

  • Page 843:

    PATEL AND TRAN

  • Page 845:

    DIZON, POLITI, AND BACK, MD

  • Page 847:

    DIZON, POLITI, AND BACK, MD

  • Page 849:

    DIZON, POLITI, AND BACK, MD

  • Page 851:

    The Advanced Practice Professionals

  • Page 853:

    Efficient and Effective Models for

  • Page 855:

    TABLE 2. Models of Care

  • Page 857:

    REEDER-HAYES

  • Page 859:

    REEDER-HAYES

  • Page 861:

    REEDER-HAYES

  • Page 863:

    REEDER-HAYES

  • Page 865:

    SARCOMA

  • Page 867:

    BLAY, DERBEL, AND RAY-COQUARD

  • Page 869:

    BLAY, DERBEL, AND RAY-COQUARD

  • Page 871:

    RYAN AND DESAI

  • Page 873:

    RYAN AND DESAI

  • Page 875:

    RYAN AND DESAI

  • Page 877:

    RYAN AND DESAI

  • Page 879:

    SARCOMA

  • Page 881:

    HOHENBERGER, KASPER, AND AHRAR

  • Page 883:

    HOHENBERGER, KASPER, AND AHRAR

  • Page 885:

    HOHENBERGER, KASPER, AND AHRAR

  • Page 887:

    HOHENBERGER, KASPER, AND AHRAR

  • Page 889:

    C. GLENN BEGLEY

  • Page 891:

    C. GLENN BEGLEY

  • Page 893:

    LOONG AND SIU

  • Page 895:

    LOONG AND SIU

  • Page 897:

    TUMOR BIOLOGY

  • Page 899:

    OWONIKOKO AND KHURI

  • Page 901:

    OWONIKOKO AND KHURI

  • Page 903:

    OWONIKOKO AND KHURI

  • Page 905:

    This publication is supported by an

  • Page 3: American Society of
  • Page 6: Obesity and Its Impact on Breast Ca
  • Page 8: DEVELOPMENTAL THERAPEUTICS
  • Page 10: Clinical Management, Molecular Alte
  • Page 12: Disparities and Challenges in Adher
  • Page 14: Multiple Myeloma: Advances in Diagn
  • Page 16: Implementation of ePrescribing and
  • Page 18: 2013 ASCO Annual Meeting Disclosure
  • Page 20: 2013 Annual Meeting Faculty
  • Page 22: Bruce E. Hillner, MD
  • Page 24: Mitchell D. Schnall, MD, PhD
  • Page 26: 2013 Educational Book Expert Panel
  • Page 28: Sunil Sharma, MD
  • Page 30: ASCO and Conquer Cancer Foundation
  • Page 32: BREAST CANCER
  • Page 34: DI LEO ET AL
  • Page 36: DI LEO ET AL
  • Page 38: DI LEO ET AL
  • Page 40: ERICA L. MAYER
  • Page 42: ERICA L. MAYER
  • Page 44: ERICA L. MAYER
  • Page 46: SPARANO, OSTRER, AND KENNY
  • Page 48: SPARANO, OSTRER, AND KENNY
  • Page 50: SPARANO, OSTRER, AND KENNY
  • Page 52:

    SPARANO, OSTRER, AND KENNY

  • Page 54:

    BREAST CANCER

  • Page 56:

    TABLE 1. Mechanisms of Action Anti-

  • Page 58:

    FIG 1. pCR rates in trials assessin

  • Page 60:

    domly selected approximately 4,800

  • Page 62:

    TABLE 5. Developmental Status of Ta

  • Page 64:

    35. Jerusalem G, Fasolo A, Dieras V

  • Page 66:

    The Effect of Biology in the Treatm

  • Page 68:

    with women who had other histologic

  • Page 70:

    cer subtype determined by immunohis

  • Page 72:

    11. Rosen PP, Groshen S, Kinne DW,

  • Page 74:

    survival and quality of life, accou

  • Page 76:

    TABLE 2. Multigene Signatures with

  • Page 78:

    Disclosures of Potential Conflicts

  • Page 80:

    of breast cancer: Report of the Nat

  • Page 82:

    after lumpectomy or mastectomy by 5

  • Page 84:

    TABLE 2. Prospective Studies of Lum

  • Page 86:

    BREAST CANCER

  • Page 88:

    systemic and local consequences of

  • Page 90:

    FIG 3. Paracrine interactions invol

  • Page 92:

    and prostaglandin E2 contribute to

  • Page 94:

    FIG 1. Prevalence of obesity among

  • Page 96:

    treatment, the type of treatment, u

  • Page 98:

    ER- patients (HR 0.41, p 0.003). 3

  • Page 100:

    34. Thomson CA, Stopeck AT, Bea JW,

  • Page 102:

    Which Patients with Sentinel Node-P

  • Page 104:

    have suggested that irradiation of

  • Page 106:

    tinel node biopsy after neoadjuvant

  • Page 108:

    THE HISTORIC BASIS OF CONCERNS OVER

  • Page 110:

    fore, adherence to strict clinical

  • Page 112:

    28. Nguyen PL, Taghian AG, Katz MS,

  • Page 114:

    Drug Development: Neoadjuvant Oppor

  • Page 116:

    in situ residuals (0.446) and incre

  • Page 118:

    metronomic chemotherapy, followed b

  • Page 120:

    Breast Cancer (ER-/PR-HER2-) With B

  • Page 122:

    Surveillance and Monitoring in Brea

  • Page 124:

    adiation exposure, but it is most f

  • Page 126:

    Providing feedback to oncologists r

  • Page 128:

    BREAST CANCER

  • Page 130:

    signifıcantly longer for anastrozo

  • Page 132:

    the preferential use of the 500 mg

  • Page 134:

    (hazard ratio 0.43; 95% CI, 0.35-0

  • Page 136:

    hormone receptor positive advanced

  • Page 138:

    such, ER-mediated gene transcriptio

  • Page 140:

    advanced disease.” 22 In BOLERO-2

  • Page 142:

    TABLE 3. Novel Agents under Investi

  • Page 144:

    Disclosures of Potential Conflicts

  • Page 146:

    Endocrine Resistance: What Do We Kn

  • Page 148:

    provide a longer time-to-progressio

  • Page 150:

    References

  • Page 152:

    CANCER GENETICS

  • Page 154:

    diffuse gastric cancer diagnosed be

  • Page 156:

    this study demonstrated a high prev

  • Page 158:

    CANCER GENETICS

  • Page 160:

    TESTA, MALKIN, AND SCHIFFMAN

  • Page 162:

    TESTA, MALKIN, AND SCHIFFMAN

  • Page 164:

    TESTA, MALKIN, AND SCHIFFMAN

  • Page 166:

    TESTA, MALKIN, AND SCHIFFMAN

  • Page 168:

    TESTA, MALKIN, AND SCHIFFMAN

  • Page 170:

    BAILEY AND MUKHTAR

  • Page 172:

    BAILEY AND MUKHTAR

  • Page 174:

    BAILEY AND MUKHTAR

  • Page 176:

    FABIAN AND KIMLER

  • Page 178:

    FABIAN AND KIMLER

  • Page 180:

    WU, LEE, AND VIGEN

  • Page 182:

    WU, LEE, AND VIGEN

  • Page 184:

    WU, LEE, AND VIGEN

  • Page 186:

    CASTRO, GOH, AND EELES

  • Page 188:

    CASTRO, GOH, AND EELES

  • Page 190:

    CASTRO, GOH, AND EELES

  • Page 192:

    CANCER PREVENTION/EPIDEMIOLOGY

  • Page 194:

    BOYD FIG. 1. Quantitative method of

  • Page 196:

    BOYD TABLE 2. Mammographic Density

  • Page 198:

    BOYD 17. Vachon CM, Kuni CC, Anders

  • Page 200:

    HOLLENBECK, KEELY, AND SEEWALDT

  • Page 202:

    HOLLENBECK, KEELY, AND SEEWALDT

  • Page 204:

    HOLLENBECK, KEELY, AND SEEWALDT

  • Page 206:

    CENTRAL NERVOUS SYSTEM TUMORS

  • Page 208:

    The studies validated 1p/19q codele

  • Page 210:

    nonmethylated tumors. The RTOG 0525

  • Page 212:

    tive study of over 1000 adults with

  • Page 214:

    these tumors had either 1p/19q code

  • Page 216:

    CENTRAL NERVOUS SYSTEM TUMORS

  • Page 218:

    DE GROOT, REARDON, AND BATCHELOR

  • Page 220:

    DE GROOT, REARDON, AND BATCHELOR

  • Page 222:

    DE GROOT, REARDON, AND BATCHELOR

  • Page 224:

    DE GROOT, REARDON, AND BATCHELOR

  • Page 226:

    TSIMBERIDOU, RINGBORG, AND SCHILSKY

  • Page 228:

    TSIMBERIDOU, RINGBORG, AND SCHILSKY

  • Page 230:

    TSIMBERIDOU, RINGBORG, AND SCHILSKY

  • Page 232:

    TSIMBERIDOU, RINGBORG, AND SCHILSKY

  • Page 234:

    CLINICAL TRIALS

  • Page 236:

    TABLE 1. Mechanisms of Resistance t

  • Page 238:

    CLINICAL TRIALS

  • Page 240:

    Core principles of NCORP include th

  • Page 242:

    Building the evidence base for how

  • Page 244:

    References

  • Page 246:

    Cellular Composition of the Tumor M

  • Page 248:

    poorer prognosis in FL. 32 These f

  • Page 250:

    GC cells. 58 Fully differentiated F

  • Page 252:

    48. Pastula A, Marcinkiewicz J. Mye

  • Page 254:

    Developments in the Use of Antibody

  • Page 256:

    one complete remission in a patient

  • Page 258:

    Picking the Optimal Target for Anti

  • Page 260:

    TABLE 2. ADCs in Development for So

  • Page 262:

    21. Flavell DJ, Flavell SU, Boehm D

  • Page 264:

    and minimization of neutralizing an

  • Page 266:

    FIG 1. Target expression in hematol

  • Page 268:

    Disclosures of Potential Conflicts

  • Page 270:

    Molecular Profiling and the Reclass

  • Page 272:

    noncoding RNAs, post-transcriptiona

  • Page 274:

    FIG 1. The “searching under the l

  • Page 276:

    molecular disease subsets with intr

  • Page 278:

    ETHICS

  • Page 280:

    thus employ the Institute of Medici

  • Page 282:

    care system. The principle of justi

  • Page 284:

    absence of oncologists therein. How

  • Page 286:

    ETHICS

  • Page 288:

    and Palliative Care Organization (N

  • Page 290:

    palliative units, patients are more

  • Page 292:

    CONCLUSION

  • Page 294:

    ETHICS

  • Page 296:

    deaths are a result of modifıable

  • Page 298:

    values. Uncovering hidden curricula

  • Page 300:

    Communication in View of Limited Re

  • Page 302:

    outweigh the currently applied (alb

  • Page 304:

    Content/Cancer%20Policy%20and%20Cli

  • Page 306:

    “Right Drug for the Right Patient

  • Page 308:

    FIG 1. The current and proposed bio

  • Page 310:

    gene expression patterns, the resul

  • Page 312:

    Biologic Agents in the Treatment of

  • Page 314:

    stage was set for the decade we are

  • Page 316:

    5. Tournigand C, Cervantes A, Figer

  • Page 318:

    The registries can be used to ident

  • Page 320:

    that there are emerging paradigms t

  • Page 322:

    GASTROINTESTINAL (COLORECTAL) CANCE

  • Page 324:

    RAMSDALE, SANOFF, AND MUSS

  • Page 326:

    RAMSDALE, SANOFF, AND MUSS

  • Page 328:

    RAMSDALE, SANOFF, AND MUSS

  • Page 330:

    CIPRIANO AND POLITE

  • Page 332:

    CIPRIANO AND POLITE

  • Page 334:

    GASTROINTESTINAL (NONCOLORECTAL) CA

  • Page 336:

    F. ANTHONY GRECO

  • Page 338:

    F. ANTHONY GRECO

  • Page 340:

    F. ANTHONY GRECO

  • Page 342:

    HEDY LEE KINDLER

  • Page 344:

    HEDY LEE KINDLER

  • Page 346:

    HEDY LEE KINDLER

  • Page 348:

    HEDY LEE KINDLER

  • Page 350:

    MICHAEL J. OVERMAN

  • Page 352:

    MICHAEL J. OVERMAN

  • Page 354:

    GASTROINTESTINAL (NONCOLORECTAL) CA

  • Page 356:

    that there is no underlying liver d

  • Page 358:

    survival was greater in the patient

  • Page 360:

    Novel Therapeutics in Hepatocellula

  • Page 362:

    TABLE 2. Dose Reductions, Delays, a

  • Page 364:

    obtaining tumor tissue specimens fr

  • Page 366:

    GASTROINTESTINAL (NONCOLORECTAL) CA

  • Page 368:

    TABLE 1. Potential Advantages and D

  • Page 370:

    more blood loss (1900 mL vs. 1000 m

  • Page 372:

    to mortality) was independently ass

  • Page 374:

    The Rationale and Evidence for Radi

  • Page 376:

    surgery, to surgery alone. Median o

  • Page 378:

    Unanswered Questions in the Managem

  • Page 380:

    TABLE 1. Selected Phase III Studies

  • Page 382:

    without surgery in patients with lo

  • Page 384:

    Nonhormone Therapy for Metastatic C

  • Page 386:

    denosumab is now approved for use i

  • Page 388:

    advanced prostate cancer: results o

  • Page 390:

    FIG 1. Overall survival curves for

  • Page 392:

    facilitating effıcient life cycles

  • Page 394:

    GENITOURINARY CANCER

  • Page 396:

    APOLO AND KWIATKOWSKI

  • Page 398:

    APOLO AND KWIATKOWSKI

  • Page 400:

    JAMES AND HUSSAIN

  • Page 402:

    JAMES AND HUSSAIN

  • Page 404:

    JAMES AND HUSSAIN

  • Page 406:

    JAMES AND HUSSAIN

  • Page 408:

    POWLES AND CRUSZ

  • Page 410:

    POWLES AND CRUSZ

  • Page 412:

    CHI, NGUYEN, AND HIGANO

  • Page 414:

    CHI, NGUYEN, AND HIGANO

  • Page 416:

    CHI, NGUYEN, AND HIGANO

  • Page 418:

    CHI, NGUYEN, AND HIGANO

  • Page 420:

    GERIATRIC ONCOLOGY

  • Page 422:

    temperature, age, secondary leukemi

  • Page 424:

    elderly patients entering Allo-HCT

  • Page 426:

    TABLE 1. Efficacy and Safety of Sel

  • Page 428:

    In patients age 75 or older or frai

  • Page 430:

    usually chemotherapy resistant. If

  • Page 432:

    Lymphoma Group (ALLG) and CLL Austr

  • Page 434:

    Adjuvant Chemotherapy in Older Adul

  • Page 436:

    surgery to treat stage II and IIIA

  • Page 438:

    Disclosures of Potential Conflicts

  • Page 440:

    monitoring. Comorbid medical condit

  • Page 442:

    oxaliplatin, or at least benefıt a

  • Page 444:

    The Life and Times of Low-Grade Ser

  • Page 446:

    advanced stage low-grade serous car

  • Page 448:

    13. Shimizu Y, Kamoi S, Amada S, et

  • Page 450:

    Family history, tubal sterilization

  • Page 452:

    and their risk of death was increas

  • Page 454:

    Revisiting the Role of Radiation Tr

  • Page 456:

    that the excellent outcomes were re

  • Page 458:

    GYNECOLOGIC CANCER

  • Page 460:

    (10%). Isosexual precocity can be c

  • Page 462:

    use of high-dose therapy in this se

  • Page 464:

    Breast and Female Genital Organs. L

  • Page 466:

    GYNECOLOGIC CANCER

  • Page 468:

    the intracellular receptor domain a

  • Page 470:

    References

  • Page 472:

    are sometimes grouped with other en

  • Page 474:

    OBESITY AND GYNECOLOGIC CANCER

  • Page 476:

    MECHANISMS

  • Page 478:

    GYNECOLOGIC CANCER

  • Page 480:

    BUELL-GUTBROD AND GWIN

  • Page 482:

    BUELL-GUTBROD AND GWIN

  • Page 484:

    GYNECOLOGIC CANCER

  • Page 486:

    FREYER, TEW, AND MOORE

  • Page 488:

    FREYER, TEW, AND MOORE

  • Page 490:

    FREYER, TEW, AND MOORE

  • Page 492:

    FREYER, TEW, AND MOORE

  • Page 494:

    HEAD AND NECK CANCER

  • Page 496:

    CMELAK ET AL

  • Page 498:

    CMELAK ET AL

  • Page 500:

    CMELAK ET AL

  • Page 502:

    CMELAK ET AL

  • Page 504:

    PSYRRI, SEIWERT, AND JIMENO

  • Page 506:

    PSYRRI, SEIWERT, AND JIMENO

  • Page 508:

    PSYRRI, SEIWERT, AND JIMENO

  • Page 510:

    PSYRRI, SEIWERT, AND JIMENO

  • Page 512:

    PSYRRI, SEIWERT, AND JIMENO

  • Page 514:

    HEAD AND NECK CANCER

  • Page 516:

    CARLSON ET AL

  • Page 518:

    CARLSON ET AL

  • Page 520:

    CARLSON ET AL

  • Page 522:

    HEAD AND NECK CANCER

  • Page 524:

    TABLE 1. Frequently Used Quality-of

  • Page 526:

    What QoL Domains Are Important for

  • Page 528:

    26. EuroQol-a new facility for the

  • Page 530:

    mucositis, while the other half sur

  • Page 532:

    Two agents known to inhibit TNF- pr

  • Page 534:

    HEALTH SERVICES RESEARCH

  • Page 536:

    circuit for the double reading, and

  • Page 538:

    National Plan for Prevention, Early

  • Page 540:

    BUDGETARY STRATEGIC PROGRAM FOR

  • Page 542:

    HEALTH SERVICES RESEARCH

  • Page 544:

    WINSON Y. CHEUNG

  • Page 546:

    WINSON Y. CHEUNG

  • Page 548:

    WINSON Y. CHEUNG

  • Page 550:

    ACCORDINO AND HERSHMAN

  • Page 552:

    ACCORDINO AND HERSHMAN

  • Page 554:

    ACCORDINO AND HERSHMAN

  • Page 556:

    BICKELL AND PASKETT

  • Page 558:

    BICKELL AND PASKETT

  • Page 560:

    BICKELL AND PASKETT

  • Page 562:

    SCHROECK, JACOBS, AND HOLLENBECK

  • Page 564:

    SCHROECK, JACOBS, AND HOLLENBECK

  • Page 566:

    SCHROECK, JACOBS, AND HOLLENBECK

  • Page 568:

    LEUKEMIA, MYELODYSPLASIA, AND

  • Page 570:

    patients were risk stratifıed only

  • Page 572:

    genes can coexist and are often ass

  • Page 574:

    Relatively little is known about th

  • Page 576:

    TABLE 2. Results of Pharmacologic T

  • Page 578:

    TABLE 3. Results of Allogeneic Hema

  • Page 580:

    subcutaneous weekly. In terms of ef

  • Page 582:

    and azacitidine combination in pati

  • Page 584:

    LEUKEMIA, MYELODYSPLASIA, AND

  • Page 586:

    ANJALI S. ADVANI

  • Page 588:

    ANJALI S. ADVANI

  • Page 590:

    DIETER HOELZER

  • Page 592:

    DIETER HOELZER

  • Page 594:

    MARK R. LITZOW

  • Page 596:

    MARK R. LITZOW

  • Page 598:

    MARK R. LITZOW

  • Page 600:

    LEUKEMIA, MYELODYSPLASIA, AND

  • Page 602:

    KEOHANE, MESA, AND HARRISON

  • Page 604:

    KEOHANE, MESA, AND HARRISON

  • Page 606:

    MICHAEL J. MAURO

  • Page 608:

    MICHAEL J. MAURO

  • Page 610:

    MICHAEL J. MAURO

  • Page 612:

    MICHAEL J. MAURO

  • Page 614:

    SMITH AND SHAH

  • Page 616:

    SMITH AND SHAH

  • Page 618:

    SMITH AND SHAH

  • Page 620:

    WEST, OXNARD, AND DOEBELE

  • Page 622:

    WEST, OXNARD, AND DOEBELE

  • Page 624:

    WEST, OXNARD, AND DOEBELE

  • Page 626:

    WEST, OXNARD, AND DOEBELE

  • Page 628:

    BAIK, VALLIÈRES, AND MARTINS

  • Page 630:

    BAIK, VALLIÈRES, AND MARTINS

  • Page 632:

    BAIK, VALLIÈRES, AND MARTINS

  • Page 634:

    LUNG CANCER

  • Page 636:

    demonstrate considerable improvemen

  • Page 638:

    imaging (MRI). 12 Ipilimumab should

  • Page 640:

    TABLE 2. Immune-Related Response Cr

  • Page 642:

    Biomarkers and Correlative Endpoint

  • Page 644:

    Identifying antigen-specific T cell

  • Page 646:

    marker remains controversial, howev

  • Page 648:

    34. Louahed J, Gruselle O, Gaulis S

  • Page 650:

    Lung Cancer in Developing Countries

  • Page 652:

    is a characteristic shared by most

  • Page 654:

    References

  • Page 656:

    institutional commitment to nationw

  • Page 658:

    institutions and local public hospi

  • Page 660:

    fluorouracil, and leucovorin as fı

  • Page 662:

    Lung Cancer in 2013: State of the A

  • Page 664:

    signifıcant improvements in respon

  • Page 666:

    the maintenance gemcitabine group.

  • Page 668:

    advanced non-small-cell lung cancer

  • Page 670:

    LUNG CANCER

  • Page 672:

    and progression of cancer. The tumo

  • Page 674:

    evaluated, and amplifıcation was n

  • Page 676:

    48. Dacic S, Flanagan M, Cieply K,

  • Page 678:

    p40 is a relatively unknown antibod

  • Page 680:

    The FLEX study investigated the add

  • Page 682:

    Tobacco and Lung Cancer: Risks, Tre

  • Page 684:

    Repeated exposure to tobacco smoke

  • Page 686:

    effort to reduce the burden of toba

  • Page 688:

    LUNG CANCER

  • Page 690:

    JUERGENS AND RUDIN

  • Page 692:

    JUERGENS AND RUDIN

  • Page 694:

    JUERGENS AND RUDIN

  • Page 696:

    FOWLER AND OKI

  • Page 698:

    FOWLER AND OKI

  • Page 700:

    FOWLER AND OKI

  • Page 702:

    FOWLER AND OKI

  • Page 704:

    LEE, SHAH, AND ORLOWSKI

  • Page 706:

    LEE, SHAH, AND ORLOWSKI

  • Page 708:

    LEE, SHAH, AND ORLOWSKI

  • Page 710:

    DONNA REECE

  • Page 712:

    DONNA REECE

  • Page 714:

    DONNA REECE

  • Page 716:

    SAN-MIGUEL, PAIVA, AND GUTIER´REZ

  • Page 718:

    SAN-MIGUEL, PAIVA, AND GUTIER´REZ

  • Page 720:

    SAN-MIGUEL, PAIVA, AND GUTIER´REZ

  • Page 722:

    NANCY L. BARTLETT

  • Page 724:

    NANCY L. BARTLETT

  • Page 726:

    NANCY L. BARTLETT

  • Page 728:

    NANCY L. BARTLETT

  • Page 730:

    SONDAK ET AL

  • Page 732:

    SONDAK ET AL

  • Page 734:

    SONDAK ET AL

  • Page 736:

    MELANOMA

  • Page 738:

    Cancer Network (NCCN) recommends ro

  • Page 740:

    FIG 1. Representative contemporaneo

  • Page 742:

    diffuse hepatic metastasis in a pat

  • Page 744:

    American Pathologists (CAP)/CLIA la

  • Page 746:

    protooncogene point mutation in hum

  • Page 748:

    Multidisciplinary Approach to Brain

  • Page 750:

    treated brain metastases if not ste

  • Page 752:

    It is not clear whether there is a

  • Page 754:

    Multidisciplinary Approach to Brain

  • Page 756:

    TABLE 1. Stereotactic Radiosurgery

  • Page 758:

    Disclosures of Potential Conflicts

  • Page 760:

    The Joys and Challenges of Caring f

  • Page 762:

    personal lives and about one-third

  • Page 764:

    Stories We Tell One Another: Narrat

  • Page 766:

    a007.) AOO stories and reflections

  • Page 768:

    References

  • Page 770:

    ASCO’s International Programs and

  • Page 772:

    TABLE 1. List of ASCO International

  • Page 774:

    Lastly, ASCO’s Conquer Cancer Fou

  • Page 776:

    Global Initiatives to Enhance Cance

  • Page 778:

    een adopted by countries around the

  • Page 780:

    Thrombosis and Cancer: Emerging Dat

  • Page 782:

    their inhibitors (such as plasminog

  • Page 784:

    TABLE 2. Dosing Regimens for Prophy

  • Page 786:

    Biomarkers

  • Page 788:

    thromboprophylaxis in patients with

  • Page 790:

    Stem Cell Transplant As an Immunomo

  • Page 792:

    Allogeneic HSCT -> GVL Effector Cel

  • Page 794:

    Disclosures of Potential Conflicts

  • Page 796:

    PEDIATRIC CANCER

  • Page 798:

    for radiochemical research, died of

  • Page 800:

    tissues and create concave dose dis

  • Page 802:

    Radiation Therapy: Proceedings of t

  • Page 804:

    Risk Stratification of Rhabdomyosar

  • Page 806:

    These have been well described by S

  • Page 808:

    habdomyosarcomas: results of a pool

  • Page 810:

    hepatocyte growth factor receptor (

  • Page 812:

    metastatic potential. In soft tissu

  • Page 814:

    Histology and Fusion Status in Rhab

  • Page 816:

    alveolar and embryonal components o

  • Page 818:

    PRACTICE MANAGEMENT AND

  • Page 820:

    an RLHS, multiple data sources, inc

  • Page 822:

    FIG 1. Screenshot of Cosmos tool. B

  • Page 824:

    PRACTICE MANAGEMENT AND INFORMATION

  • Page 826:

    COX, SPRANDIO, AND BARKLEY

  • Page 828:

    COX, SPRANDIO, AND BARKLEY

  • Page 830:

    COX, SPRANDIO, AND BARKLEY

  • Page 832:

    COX, SPRANDIO, AND BARKLEY

  • Page 834:

    DAVID LIEBOVITZ

  • Page 836:

    DAVID LIEBOVITZ

  • Page 838:

    PRACTICE MANAGEMENT AND

  • Page 840:

    TABLE 1. Top 10 Medicare Part B Exp

  • Page 842:

    that they would support, three of w

  • Page 844:

    PROFESSIONAL DEVELOPMENT

  • Page 846:

    A TOOLKIT FOR BETTER COMMUNICATION

  • Page 848:

    then.” Anxiety often drives patie

  • Page 850:

    PROFESSIONAL DEVELOPMENT

  • Page 852:

    POLANSKY

  • Page 854:

    LAWRENCE N SHULMAN

  • Page 856:

    PROFESSIONAL DEVELOPMENT

  • Page 858:

    more visible on the national stage.

  • Page 860:

    university students and 61% of stud

  • Page 862:

    stakeholders come together to colla

  • Page 864:

    4. Kanter SL. What is academic medi

  • Page 866:

    Do Our Current Clinical Trial Desig

  • Page 868:

    sarcoma histotypes do achieve a rel

  • Page 870:

    15. Chawla SP, Staddon AP, Baker, e

  • Page 872:

    CYTOTOXIC CHEMOTHERAPY

  • Page 874:

    doxorubicin TH-302 in patients wit

  • Page 876:

    espond. 81 As was seen with crizoti

  • Page 878:

    54. Clinical Trials: A service of t

  • Page 880:

    Surgical Management and Minimally I

  • Page 882:

    overestimating the results of resec

  • Page 884:

    RF ablation is currently the most w

  • Page 886:

    Deep-wave hyperthermia plus chemoth

  • Page 888:

    TUMOR BIOLOGY

  • Page 890:

    If results were still not confırme

  • Page 892:

    Selecting the Best Drugs for Phase

  • Page 894:

    immunohistochemical expression of a

  • Page 896:

    number of compounds available for t

  • Page 898:

    Targeting the PI3K/AKT/mTOR Pathway

  • Page 900:

    PTEN loss and activating PIK3CA is

  • Page 902:

    presence of KRAS mutation was repro

  • Page 904:

    25. Kwei KA, Baker JB, Pelham RJ. M

Foreign Consulates - ASCO Annual Meeting

Foreign Consulates - ASCO Annual Meeting

Guide for International Attendees of the 2013 ASCO Annual Meeting

Guide for International Attendees of the 2013 ASCO Annual Meeting

exhibitor policies & information - ASCO Annual Meeting - American ...

exhibitor policies & information - ASCO Annual Meeting - American ...

Ancillary Event Marketing Package - ASCO Annual Meeting ...

Ancillary Event Marketing Package - ASCO Annual Meeting ...

© 2006-2014 by i-Magazine AG